Total compensation: $13,538,010 for the year ended Dec. 31, 2015
Salary: $1,110,000
Non-equity incentive pay: $1,453,545
Other compensation: $10,950
Exercised stock options: $9,195,278
Value realized on vesting shares: $1,768,237
New stock options: 0
Total 2015 shareholder return: -3.3 percent
Note: Starks retired as president and CEO of the Little Canada-based medical device company at the end of 2015 and as a result did not receive any new stock options or restricted stock awards in connection with the company's equity grant cycle in December.
Michael Rousseau, formerly the chief financial officer, was promoted to president and CEO while Starks remains executive chairman.
While Starks was not granted any new stock options, he did realize $9.2 million when he exercised 320,000 previously issued stock options. That exercise helped to nearly double the total realized compensation of $6.8 million he earned in 2014.
Starks had been chairman, president and CEO of St. Jude since 2004 and, according to the St. Jude proxy statement, revenue grew from $2.3 billion to $5.5 billion during his tenure.
Some say the MAHA movement and GLP-1 drugs hurt sugar beet farmers. The White House is blaming former President Joe Biden.
